← Eichor
Study identifier: NCT05189496 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis

Condition: Radiation Pneumonitis  ·  Sponsor: Guangdong Provincial People's Hospital

PhaseNA
Planned participants380
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients, but also has the risk of radiation lung injury, which can develop into pulmonary fibrosis. Hyperbaric oxygen can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. We aim to investigate whether hyperbaric oxygen treatment can reduce the incidence of radiation pneumonia and improve patients' quality of life, and to evaluate its safety and the impact on the patients' long-term survival outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Kun Wang  ·  13922118086  ·  gzwangkun@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Guangdong Provincial People's HospitalGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05189496